is a novel test for prostate cancer based on biomarkers discovered by Cambridge Oncometrix. 

The test uses the fact that tumor cells cause changes in chemical composition of prostatic and seminal fluid.

These changes can be readily measured by CAMONX test.

To establish prostate condition measured values of CAMONX biomarkers are combined into an index, which is indicative of disease.